People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotech / Pharma, Biotechnology, Other Energy, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pivot Bio, Inc. | — | Biotech / Pharma | Growth/Late | $622.6M | $13.0B | 2016 |
| AbCellera Biologics Inc. | — | Biotechnology | Series C | $83.0M | $3.1B | 2018 |
| Empirico Inc. | — | Biotechnology | Series C | $74.8M | $665.0M | 2018 |
| Cobalt Technologies Inc | — | Other Energy | Series B | $68.0M | $10.4M | 2011 |
| Chromatin, Inc. | — | Other | Series B | $61.3M | $228.4M | 2011 |
| Avicenna Biosciences, Inc. | — | Biotechnology | Series A | $17.5M | $31.5M | 2022 |
| Osprey Pharmaceuticals Usa Inc | — | Pharmaceuticals | Series A | $5.9M | $182.5M | 2009 |
John Hamer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Hamer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dennis Langer | 2 | 9 |
| Matt Ocko | 1 | 13 |
| Robert Shapiro | 1 | 13 |
| Fouad Azzam | 1 | 8 |
| Greg Young | 1 | 8 |
| George Arida | 1 | 6 |
| Roger Wyse | 1 | 5 |
| Robert Mayer | 1 | 4 |
| Doug Janzen | 1 | 4 |
| Michael Hayden | 1 | 4 |
| Nassim Usman | 1 | 4 |
| Ken Pelowski | 1 | 3 |
| David Woodburn | 1 | 3 |
| Meghan Sharp | 1 | 3 |
| Andy Meyer | 1 | 2 |
| Christopher Meldrum | 1 | 2 |
| Daphne Preuss | 1 | 2 |
| Armand Lavoie | 1 | 2 |
| George Landegger | 1 | 2 |
| Henry Hirvela | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.